with 34% blasts and trilineage dysplasia (Figure 1a ). Karyotypic analysis showed 11 of 20 metaphases containing the del(5)(q13q33), whereas allele-specific PCR demonstrated the presence of JAK2 V617F . After discussion of the therapeutic alternatives with the patient (including the likelihood of failure with induction chemotherapy with secondary AML (median survival 3-4 weeks 3 with standard therapy in age 480 years), and the responses reported with lenalidomide for patients with interstitial chromosome 5q deletions and MDS, 1 she elected to begin lenalidomide at a dose of 10 mg/day. She tolerated the agent well, without any adverse effects. After 3 months of treatment, she had normal peripheral blood counts, and no evidence of circulating blasts. A repeat marrow exam showed a slightly hypercellular marrow, with significant improvement in granulocytic maturation and with a significant decrease in the myeloblasts to 5% blasts ( Figure 1b) . Additionally, the karyotypic abnormalities had completely resolved to show a normal female karyotype. This would be considered a partial response by the International Working Group for Acute Myeloid Leukemia, 4 nearly a complete response had the blast percentage been o5%. After 2 additional months of lenalidomide (still at 10 mg/day) the patient had evidence of disease progression, with recurrent leukopenia, thrombocytopenia and 10% blasts in the marrow. Additionally, repeat karyotypic analysis showed clonal progression, with 10/30 metaphases having the del(5)(q13q33), and 7 of them with multiple other structural abnormalities including loss of 17p. Alternative therapy was initiated.
To our knowledge, this is the first report of lenalidomide monotherapy resulting in achieveving a solid 5-month partial remission in an elderly patient with high-risk AML. The patient reported a high quality of life during this time, and was free of transfusions, hospitalization and infection. The coexistence of the JAK2 V617F mutation, a finding more commonly associated with myeloproliferative disorders, is an additional intriguing aspect to this case. JAK2 V167F has been described in 6.2% MDS patients with del(5)(q13q33), 5 and the clinical significance is unknown. Few agents offer any legitimate therapeutic benefit to elderly patients with secondary AML. Lenalidomide may have activity as monotherapy against AML arising from del(5q)-associated chronic myeloid disorders. However, the apparent ability of the disorders to undergo clonal evolution suggests that combination or sequential therapy of lenalidomide with other novel or traditional agents should be explored. Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal haematopoietic stem cell disorders with variable clinical course depending on ineffective haematopoiesis or transition to acute myeloid leukaemia (AML). 1 Prognosis of MDS is closely correlated with bone marrow blast cell count, cytogenetic abnormalities and the degree of cytopenia, expressed in the International Prognosis Scoring System (IPSS). However, it is still difficult to predict survival in individual patients and the definition of additional parameters remains relevant for decisions in MDS-directed therapies.
The cell-cell adhesion molecule E-cadherin (120 kDa) and cell-matrix adhesion molecule CD44 (90 kDa) are involved in the regulation of haematopoiesis and are expressed on diverse types of mature blood cells and CD34 þ stem cells. 2, 3 Their aberrant expression plays a pivotal role in various solid and haematological malignancies like multiple myeloma, AML and lymphoma. [4] [5] [6] [7] In malignant cells, these membrane-anchored proteins undergo activated proteolysis of the extracellular domain resulting in elevated serum levels of the soluble and bioactive polypeptides serum CD44 (sCD44) (25 kDa) or serum E-cadherin (sE-cad) (80-84 kDa). 4 The multifunctional properties of both adhesion molecules with expression on diverse types of blood cells suggest a critical role in the pathogenesis of MDS. Takubo et al. 8 described elevated serum levels of E-cadherin in a small MDS cohort (n ¼ 13) without analysis of its clinical significance. Similarly, there is also only one study reporting slightly increased CD44 serum levels in MDS (n ¼ 43), 9 without subgroup analysis and no investigation of its impact on survival. In this report, the prognostic significance of serum levels of sCD44 standard (sCD44 s), the variant isoform CD44v6 (sCD44v6) and E-cadherin (sE-cad) was analysed in a cohort of 66 MDS patients. The study was approved by the local ethics committee and comprised clinical data and serum samples from consecutive, newly diagnosed and treatment-naive MDS patients who had given written informed consent before any study procedure. Patients with severely impaired liver or kidney function or elevated C-reactive protein were excluded from the study. MDS stage was classified according to the criteria of the French-American-British (FAB) group. 1 Median age of patients was 71 years (range 19-93 years), female to male ratio 1:1.44. Fifteen patients presented with refractory anaemia (RA), five patients with RA with ringed sideroblasts (RARS), 21 patients Letters to the Editor with RA with excess of blasts (RAEB), 11 patients with RAEB in transition (RAEB-t), nine patients with chronic myelomonocytic leukaemia (CMML) and five patients with overt secondary acute leukaemia. The control group consisted of 19 age-matched persons without any evidence of inflammatory or neoplastic disease. Quantification of sCD44 s, sCD44v6 and sE-cad in serum samples was determined by enzyme-linked immunosorbent assay following the manufacturer's instruction (Bender MedSystems, Vienna, Austria; R&D Systems, Minneapolis, MS, USA). Statistical analysis was performed using SPSS 12.0 software (SPSS Inc., Chicago, IL, USA). The two-sided Mann-Whitney U-test was used to compare means between different FAB groups. Correlation coefficients were calculated with Spearman's rank correlation. Survivals were plotted by the Kaplan-Meier (KM) method and compared by the log-rank test. The observation period lasted at least 1 year. Cutoff levels for sCD44 s and sE-cad were defined as the mean level of healthy persons plus 2 s.d. Multivariate survival analysis was performed using the Cox proportional hazard model, including sCD44 s, sE-cad, age, sex, lactate dehydrogenase (LDH) and IPSS. Based on the hazard ratio, the mortality risk for an individual patient depending on levels of sCD44 s or sE-cad was calculated by hazard ratio (95% confidence interval) (increase of serum value in ng/ml).
Levels of serum CD44 s and E-cadherin were significantly elevated in patients with MDS as compared to healthy donors (Figure 1 ), whereas sCD44v6 showed no significant difference. sCD44 s was characterized by a differential expression in various FAB subgroups, revealing the highest levels in CMML and in secondary AML (Figure 1 ), thus extending data from previous reports. 9 Median level of sCD44 s in controls was 487 ng/ml (range 325-890 ng/ml), in RA 736 ng/ml (range 417-1210 ng/ml), in RARS 598 ng/ml (range 493-911 ng/ml), in RAEB 638 ng/ml (range 301-1077 ng/ml), in RAEB-t 774 ng/ ml (range 417-1138 ng/ml), in CMML 1470 ng/ml (range 599-7961 ng/ml) and in secondary AML 960 ng/ml (range 459-1757 ng/ml).
sE-cad was elevated in patients with RA, RAEB and CMML, but not in those with RAEB-t or secondary AML (Figure 1 ). Median level of sE-cad in controls was 83 ng/ml (range 57-188 ng/ml), in RA 115 ng/ml (range 67-286 ng/ml), in RAEB 111 ng/ml (range 55-221 ng/ml), in CMML 136 ng/ml (range 87-230 ng/ml), in RARS 104 ng/ml (range 79-131 ng/ml), in RAEB-t 87 ng/ml (range 60-146 ng/ml) and in secondary AML 95 ng/ml (range 63-128 ng/ml). The lack of significant elevation of sE-cad levels in MDS with increased bone marrow blasts (RAEB-t or sAML) could point to silencing of E-cadherin expression in leukaemogenesis. 10 In acute myelogeneous leukaemia, hypermethylation of the E-cadherin gene and consequent loss of E-cadherin RNA and protein has been demonstrated.
We report for the first time, that both circulating adhesion molecules are highest present in CMML. The clinical relevance of strong activation of soluble adhesion molecules might be expressed in the frequent development of extramedullary infiltrations in patients with CMML, involving spleen, skin, lung and brain. Recently, ligation of CD44 with specific anti-CD44 monoclonal antibodies emerged as an efficient way to inhibit the proliferation of AML cells. Thus, CMML could also be a candidate for CD44-targeting therapeutic concepts. Levels of sCD44 s and sE-cad were not associated with the number of bone marrow blasts, cytogenetics, IPSS, platelet counts, haemoglobin or LDH level, age or sex, but were correlated with elevated leucocyte count (r ¼ 0.454, Po0.001 and r ¼ 0.273, P ¼ 0.03, respectively), especially with the monocyte count (r ¼ 0.583, P ¼ 0.05 and r ¼ 0.77, P ¼ 0.016, respectively). This finding was most expressed in the CMML group, in the hyperproliferative as well as in the hypoplastic subtype.
To analyse the prognostic relevance of both markers, KM plots were performed, excluding patients with secondary AML or patients who underwent stem cell transplantation.
Increased sCD44 s or sE-cad levels (cutoff level 819.4 or 141.3 ng/ml, respectively) correlated with shortened survival (17 versus 39 months survival, P ¼ 0.009 or 4 versus 24 months, P ¼ 0.004, respectively; Figure 2a Letters to the Editor or sE-cad levels. In a Cox proportional hazard model, the IPSS score was confirmed as the most relevant prognostic factor. In addition, sCD44 s and sE-cad were identified as independent predictors (Table 1) . Accordingly, based on hazard ratio an increase in sCD44 s from 500 to 1500 ng/ml would result in an up to 2.7-fold risk of mortality. Similarly, elevation of sE-cad from 80 to 140 ng/ml would reflect an up to 5.2-fold risk of death.
In conclusion, this is the first study providing evidence for a prognostic value of the adhesion molecules CD44 and E-cadherin in MDS. Distinct FAB subtypes revealed differential sCD44 s and sE-cad expression, with CMML exerting the highest levels of both adhesion molecules. Elevated levels of sCD44 s or sE-cad (cutoff level 4819.4 ng/ml or 4141.3 ng/ml, respectively) were correlated with shorter survival and reflected prognostic significance independent from IPSS, which should be further tested in risk stratification models and prospective studies. Elevated serum levels of sCD44 s (a) and sE-cad (b) are associated with shorter survival in MDS patients, as analysed by KM procedure. Cutoff levels were defined on the basis of healthy controls plus 2 s.d. A somatic point mutation in the tyrosine kinase JAK2 (1849 G to T) has been described in myeloproliferative diseases (MPD), resulting in a non-synonymous amino-acid substitution (V to F) at position 617. This mutation (JAK2V617F) is located in the JH2 pseudo-kinase auto-inhibitory domain, rendering the enzyme constitutively active and leading to cytokine hypersensitivity and erythrocytosis in mice. 1 There is considerable variation in the reports of JAK2V617F frequency in MPD, with incidence rates of 23-57% in essential thrombocythemia, 35-57% in idiopathic myelofibrosis and 65-97% in polycythemia vera (PV). 2 Of particular interest is the expression of JAK2V617F mutation in PV, with its hallmark of erythrocytosis, which involves the JAK2-signaling pathway. Possible reasons for discrepancies in the observed mutation frequency in PV by different research groups include (1) differences in assay sensitivity, 3 (2) diagnostic inaccuracy and (3) treatment effect. 4 In order to examine these possibilities, we have re-examined 17 previously published JAK2V617F-negative PV cases, including nine from the Mayo Clinic, 5, 6 four from the MD Anderson Cancer Center (MDACC) 7 and four from the Weill Medical College. 8 Among the nine Mayo Clinic cases, the diagnosis was inaccurate in four and questionable in one. Repeat testing with more sensitive techniques revealed the presence of the mutation in three of the remaining four patients. In the last patient, there was not enough material for re-testing. Among the four MDACC cases, two were positive for JAK2V617F mutation on re-testing using a more sensitive technique; mutation screening in the other two patients was performed at the time of leukemic transformation and the historical diagnosis of PV had not been well documented. Of the four cases reported by the Weill Medical College researchers, two were receiving interferon-a therapy for several years before testing for the mutation, and two had interferon discontinued 2 years before testing for JAK2 because of excellent clinical response. Thus, treatment could have resulted in the suppression of the mutant clone. 4 Therefore, we conclude that a diagnosis of 'PV' in the absence of the JAK2V617F warrants a re-evaluation that takes into account the possibility for misdiagnosis, treatment-related effect and an insufficiently sensitive mutation screening assay. Once these three issues are addressed, it seems likely that the JAK2V617F mutation may be present in virtually all PV patients. 
